Ultra-Low Dose of Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity
| Autor: | Vasileios T Papastavrou, Ayad Shafiq, Alan J. Connor, Roxane J. Hillier |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty genetic structures Bevacizumab Ultra low dose Angiogenesis Inhibitors Gestational Age Antibodies Monoclonal Humanized Ophthalmology Humans Medicine Retinopathy of Prematurity Intravitreal bevacizumab business.industry Infant Newborn Retinopathy of prematurity General Medicine medicine.disease Effective dose (pharmacology) eye diseases Infant Extremely Low Birth Weight Intravitreal Injections Pediatrics Perinatology and Child Health sense organs business medicine.drug |
| Zdroj: | Journal of Pediatric Ophthalmology & Strabismus. 52 |
| ISSN: | 1938-2405 0191-3913 |
| DOI: | 10.3928/01913913-20150421-11 |
| Popis: | Intravitreal bevacizumab is an increasingly common treatment choice for posterior retinopathy of prematurity. Despite concern about its systemic effects, there have been few studies on the lowest effective dose. The authors describe a case that was successfully treated with 0.16 mg of bevacizumab, the first time this dose has been reported. [ J Pediatric Ophthalmol Strabismus. 2015;52:e20–e21.] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|